2013-2014年美国男性生殖器人乳头瘤病毒感染率
该研究利用2013-2014年美国国家健康与营养调查中14-59岁男性的阴茎拭子,首次报告美国男性生殖器HPV感染的全国代表性患病率。结果显示,任意HPV患病率为42.2%(95%CI 38.3%-46.1%),高危型HPV为23.4%(95%CI 21.3%-25.6%),且任意HPV患病率与性伴侣数量相关。四价疫苗型别(6/11/16/18)的年龄别患病率差异提示疫苗接种规划已对男性中这些型别的流行产生影响。
要点
- 美国14-59岁男性任意生殖器HPV患病率为42.2%,高危型为23.4%。
- 任意HPV患病率随年龄增长至25-29岁,此后至59岁保持相近。
- 终身性伴侣数≥15较1-2者任意HPV患病率PR为3.27(95%CI 2.12-5.02)。
核心结论
- 美国14-59岁男性中42.2%可检出生殖器HPV感染。
- 4vHPV型别与非4vHPV型别年龄别患病率差异提示疫苗接种规划对男性HPV 6/11/16/18型别流行产生影响。
研究设计与样本
- 基于2013-2014年美国国家健康与营养调查(NHANES)的全国代表性横断面研究。
- 使用14-59岁男性阴茎拭子估计HPV DNA患病率及患病率比(PR)。
主要发现
- 任意HPV患病率为42.2%(95%CI 38.3%-46.1%),高危型HPV患病率为23.4%(95%CI 21.3%-25.6%)。
- 14-19岁任意HPV患病率为12.5%,随年龄增长至25-29岁,此后至59岁相近。
- 调整年龄和种族后,任意HPV患病率与终身性伴侣数(≥15 vs 1-2;PR 3.27;95%CI 2.12-5.02)及过去一年性伴侣数(≥2 vs 0;PR 1.26;95%CI 1.09-1.46)相关。
- 四价HPV疫苗型别(6/11/16/18)患病率仅在25-29岁与20-24岁之间显著更高(PR 2.79;95%CI 1.31-5.96)。
- 其他HPV型别患病率仅在20-24岁与14-19岁之间显著更高(PR 3.39;95%CI 2.49-4.61)。
临床怎么用
- 提示临床关注男性生殖器HPV感染的高患病率,尤其在性活跃年龄段。
- 年龄别4vHPV型别患病率差异可供评估男性HPV疫苗接种规划效果参考。
局限性
- 横断面设计无法推断因果关系。
- 基于阴茎拭子检测,可能未覆盖全部生殖器HPV感染部位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report the first nationally representative prevalence data on genital human papillomavirus (HPV) in males in the United States, using findings from the National Health and Nutrition Examination Surveys, 2013-2014. METHODS: Using penile swabs from males aged 14-59 years, we estimated the HPV DNA prevalence and prevalence ratios (PRs) with respect to sexual behaviors and demographic characteristics. RESULTS: The prevalence of any HPV was 42.2% (95% confidence interval [CI], 38.3%-46.1%) and of high-risk (HR) HPV was 23.4% (95% CI, 21.3%-25.6%). Prevalence of any HPV was 12.5% in 14-19 year olds and was higher in older age groups, through ages 25-29 years, and then similar through age 59 years. After adjustment for age and race, any HPV prevalence was associated with lifetime number of sex partners (≥15 vs 1-2; PR, 3.27; 95% CI, 2.12-5.02) and past-year number of sex partners (≥2 vs 0; PR, 1.26; 95% CI, 1.09-1.46). Comparisons of consecutively older age groups revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16, and 18, was significantly higher only between ages 25-29 and 20-24 years (PR, 2.79; 95% CI, 1.31-5.96), whereas the prevalence of other HPV types was significantly higher only between ages 20-24 and 14-19 years (PR, 3.39; 95% CI, 2.49-4.61). CONCLUSIONS: Overall, 42.2% of US males aged 14-59 years have detectable genital HPV infections. Differences in the age-specific prevalence of 4vHPV types and non-4vHPV types suggest that the vaccination program has had an impact on the prevalence of HPV types 6, 11, 16, and 18 among males.
引用
- Gargano JW, Unger ER, Liu G, et al. Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014. J Infect Dis. 2017. PMID: 28170037. doi:10.1093/infdis/jix057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。